Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (254)	4/18/2002 6:41:58 PM
From: nigel bates	Read Replies (1) \| Respond to of 625

Certainly as informed as I am. <g> The $1bn figure wasn't mine, FWIW. I saw the estimate in a couple of places. I'll try to hunt them down, & post them. These were my notes (!) on anti-IL-12 from the H&Q presentation - J695 (Abbott) - mid P11 in RA & Crohns (?). Can't say much as it's pharma. From memory, there was definitely a strong hint they were actively pursuing indications other than than RA, but it's clearly one of those no publicity deals... $10m is probably right for now, but you never know. nig

To: keokalani'nui who wrote (254)	4/18/2002 8:41:04 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 625

<<, but CDP870 is coming and if the nurse can lift the syringe one month dosing is going to be very attractive.>> LOL Anti-p38 (maybe anti-IL-1/18) may be first big step forward in inflammatory field, IF one can develop selective (sub-specific, but it should tickle few more MAP kinases) and potent inhibitor. Regards the E versus R, or other antiTNF, interesting study: jpet.aspetjournals.org Vol. 301, Issue 2, 418-426, May 2002 Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists Bernie Scallon, Ann Cai, Nancy Solowski, Amy Rosenberg, Xiao-Yu Song, David Shealy and Carrie Wagner Research and Development, Centocor, Inc., Malvern, Pennsylvania Two tumor necrosis factor (TNF) antagonists infliximab (a chimeric monoclonal antibody) and etanercept (a p75 TNF receptor/Fc fusion protein) have been approved for treatment of rheumatoid arthritis. However, these agents have shown different degrees of clinical benefit in controlled clinical trials in other TNF-mediated diseases such as Crohn's disease (CD) and psoriasis. We investigated whether structural differences between these two antagonists translate into different binding and functional characteristics. To study the binding of infliximab and etanercept to both the soluble and cell-surface transmembrane forms of TNF, a variety of in vitro binding and cell-based assays were performed. Binding assays using 125I-labeled TNF showed that infliximab binds to both monomer and trimer forms of soluble TNF (sTNF), whereas etanercept binding is restricted to the trimer form. Infliximab formed stable complexes with sTNF, whereas etanercept formed relatively unstable complexes, resulting in release of dissociated TNF. KYM-1D4 cell killing assays and human umbilical vein endothelial cell activation assays demonstrated that TNF that had dissociated from etanercept was bioactive. Infliximab also formed more stable complexes with the transmembrane form of TNF expressed on transfected cells relative to analogous complexes formed with etanercept. Additionally, more infliximab molecules bound to the transmembrane TNF with higher avidity than etanercept. Although both infliximab and etanercept inhibited transmembrane TNF-mediated activation of human endothelial cells, infliximab was significantly more effective. The differences between infliximab and etanercept in their TNF binding characteristics may help explain their differential efficacy in CD and psoriasis clinical trials.